Cargando…
How Does the Public Evaluate Vaccines for Low-Incidence, Severe-Outcome Diseases? A General-Population Choice Experiment
BACKGROUND: Because immunizing large numbers of healthy people could be required to reduce a relatively small number of infections, disease incidence has a large impact on cost effectiveness, even if the infection is associated with very serious health outcomes. In addition to cost effectiveness, th...
Autores principales: | Johnson, F. Reed, Fairchild, Angelyn, Whittington, Dale, Srivastava, Amit K., Gonzalez, Juan Marcos, Huang, Liping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744670/ https://www.ncbi.nlm.nih.gov/pubmed/36509960 http://dx.doi.org/10.1007/s40271-022-00602-x |
Ejemplares similares
-
2. Understanding Patient Preferences for Meningococcal Serogroup B Vaccines in the United States
por: Johnson, Reed, et al.
Publicado: (2020) -
Method for Calculating the Simultaneous Maximum Acceptable Risk
Threshold (SMART) from Discrete-Choice Experiment Benefit-Risk
Studies
por: Fairchild, Angelyn Otteson, et al.
Publicado: (2022) -
Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
por: Mohamed, Ateesha F., et al.
Publicado: (2015) -
Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
por: Gonzalez, Juan Marcos, et al.
Publicado: (2022) -
Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions
por: Montano-Campos, J. Felipe, et al.
Publicado: (2023)